Pacer Advisors
LXEO icon

Pacer Advisors’s Lexeo Therapeutics LXEO Stock Holding History

Pacer Advisors’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5K Buy
+1,128
New +$6.1K ﹤0.01% 2400

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Pacer Advisors's LXEO Position: Q2 2026 in Review

Pacer Advisors opened a new position in Lexeo Therapeutics (LXEO) in Q2 2026: 1,128 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #2400 among its holdings.

142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Pacer Advisors held 1,128 shares of Lexeo Therapeutics worth $5K as of Q2 2026.
  • Lexeo Therapeutics was a new Pacer Advisors position in Q2 2026.
  • Lexeo Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2400 holding.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.